Although some of the clinical studies previously executed provide us with enough evidence to incorporate plasma GFAP as non-invasive monitoring biomarker for diagnosis and prognosis of AD in the clinic, there is still a need for validating clinical trials. The gene discussed is GFAP; the disease is Alzheimer disease.